Drug Profile
IONIS APOARx
Alternative Names: IONIS-APO(a)Rx; IONIS-APOA Rx; ISIS-494372; ISIS-APO(a)RX; ISIS-APOA RxLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Class Antihyperlipidaemics; Antisense oligonucleotides
- Mechanism of Action Apolipoprotein A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hyperlipoproteinaemia
Most Recent Events
- 10 Dec 2015 Discontinued - Phase-II for Hyperlipoproteinaemia in Canada, Denmark, Germany, Netherlands, United Kingdom (SC)
- 08 Nov 2015 Efficacy and adverse event data from a phase II trial in Hyperlipoproteinaemia presented at the American Heart Association Scientific Sessions (AHA-2015)
- 07 Aug 2014 Phase-II clinical trials in Hyperlipoproteinaemia in Denmark and Germany (SC) (EudraCT2014-000701-13)